Industry Symposia 2026 - 3rd of September
British Summer Time (BST)
No CPD credits
IUCS is a sponsored event. All companies sponsoring the event are named and have no input into the content of the programme, arrangement of the event, or the selection of speakers, except in the case of dedicated sponsored symposium sessions, which are clearly identified in the conference programme. IUCS receives exhibition sponsorship from pharmaceutical companies and other trade partners.
IUCS recognise the ABPI Code of Practice and the implications for pharmaceutical companies that support the Annual meeting by way of sponsoring. Industry partners have no input into the educational content of the programme outside of sponsored industry symposium and stands.
13:45 - 14:20
This promotional session has been organised and fully funded by MSD. MSD was not involved in organising the rest of the IUCS conference. This symposium is intended for UK Healthcare Professionals only. MSD products will be discussed at this symposium. The views of the speakers are their own and do not represent the opinions of MSD. MSD has provided funding as a sponsor of IUCS 2026 but has had no input into the agenda or scientific content.
Translating KEYNOTE-905 into Practice: Urology and Oncology Perspectives on Perioperative Treatment and Decision-Making in Cisplatin-Ineligible MIBC
Prof Robert Jones, Professor of Clinical Cancer Research, Honorary Consultant Medical Oncologist, NHS Greater Glasgow and Clyde
Prof James Catto, Professor of Surgery, University of Sheffield; Honorary Urological Surgeon, Sheffield Teaching Hospitals NHS Trust
16:10 - 16:30
Bridging the gap: when should urologists refer in mCRPC?
Miss Jyoti Shah MBE, Macmillan Consultant Urological Surgeon, North West Anglia NHS Foundation Trust, UK
17:20 - 17:40
IN PRESENCE ONLY
Heart and Hormones: Optimising Nubeqa (Darolutamide)in Patients Living with Cardiovascular Comorbidities and Prostate Cancer
Dr Kenrick Ng, Consultant Medical Oncologist, Barts Health NHS Trust, United Kingdom.